Scil Proteins is a biopharmaceutical platform company geared toward early product developments (Phase I/ II). A second complementary business component lies in its manufacturing operations.
The key elements for an ongoing growth of the Affilin® business are twofold: the expertise in protein engineering and drug development and the attendant manufacturing business. The latter supports the Affilin® projects and generates revenues via external partners such as Roche, Novartis, Pfizer, Intercell and Aventis.
This business model capitalizes on the current dearth of clinical candidates throughout the industry, the high prices for Phase I/II compounds and the increasing outsourcing of manufacturing activities.
The business model is organized in two integrated legal entities:
